Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRg-FU for Recurrent Rectal Cancer
NCT02528175Completed
- Sponsor
- William Chu
- Start
- Apr 2015
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by William Chu. Primary endpoint: Acute toxicities at 3 months. Started Apr 2015; status: completed.
Beyond the preview
Go deeper on NCT02528175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528175.